(Photo Courtesy: www.trackurly.com)
Saxagliptin (Onglyza) is a drug used in treating type-2 diabetes. Initially, the molecule was discovered and developed by Bristol-Myers Squibb (BMS) and was later, in 2007, joined by AstraZeneca (AZ) to further develop and commercialize the product.
Between the co-developmental period 2007 through 2009, AZ solely bore the developmental costs, post which both the companies shared their spending for other additional costs incurred.
In the beginning of 2014, AZ acquired the entire BMS' diabetes business through a staggering $4 billion transaction.
The acquisition gave AZ complete ownership of all the intellectual properties (IP) and global rights for developing, manufacturing and commercializing BMS' diabetes drugs, which included Saxagliptin among others.